RINVOQ (Abbvie Pty Ltd)
Product name
RINVOQ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
191 (255 working days)
Active ingredients
upadacitinib hemihydrate
Registration type
EOI
Indication
Psoriatic Arthritis
RINVOQ (tablet) is now also indicated for the treatment of moderate to severe active psoriatic arthritis in adult patients who have responded inadequately to, or are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with a non-biological DMARD.
Ankylosing Spondylitis
RINVOQ is now also indicated for the treatment of adults with active ankylosing spondylitis.